DURAGESIC-37
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-37 is a transdermal extended-release film formulation approved in 1990 by Johnson & Johnson. The specific indication and mechanism of action are not publicly detailed in available data, limiting characterization of its therapeutic role.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, likely signaling smaller commercial teams and transition planning rather than growth-phase expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature, LOE-approaching stage with minimal hiring activity. Career growth on this product is limited; opportunities exist primarily in transition planning and managed portfolio roles.
Brand ManagerField Sales
Worked on DURAGESIC-37 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.